PHILADELPHIA – Researchers at the University of Pennsylvania School of Medicine can now explain how the body determines whether there are enough mature B-cells in the blood stream at any one time. These are the cells that produce antibodies against germs to fight infections.
Molecular crosstalk between two B-cell surface receptors (green, Y-shaped B-cell receptor and orange cylinder-shaped BLyS receptor) balances the need to have enough B cells to drive a healthy immune response while at the same time guarding against autoimmunity.
Click on thumbnail
to view full-size image
“There is a steady state number of B cells that is considered normal for humans,” says senior author Michael P. Cancro, PhD, Professor of Pathology and Laboratory Medicine. “We found that molecular crosstalk between two receptors on the surface of B cells balances the need to have enough B cells to make good immune responses, while at the same time guarding against autoimmunity.”
The B-cell crosstalk paper appeared online this week in Nature Immunology. This and other work from the Cancro lab has important implications for transplantation science and battling autoimmune diseases.
Cancro, first author Jason E. Stadanlick, a PhD student in the Cancro lab, and others found that when more of a protein called BLyS, which binds to a receptor on B-cell surfaces is circulating, more mature B cells can be kept alive. By adding more BLyS to the system, the “brakes” governing how many immature B cells are allowed to become mature B cells are relaxed. On the other hand, the body guards against autoimmune diseases such as lupus by preventing the survival of B cells via the other receptor in this equation.
The research from the Cancro lab reveals a complicated interplay between these two receptors that allows them to integrate their signals, which are at odds with one another. “One receptor sends signals to the cell nucleus that says, ‘yes stay alive, the body needs more B cells,’ while the other says ‘wait a minute, be careful which B cells are allowed to live.’”
The Cancro lab also described in a recent Proceedings of the National Academy of Sciences (PNAS) paper that if BLyS is neutralized, most B cells die, but the ones in charge of remembering what the body has already been vaccinated against or has been exposed to, remain alive.
Together, these findings should eventually lead to interventions that alter or adjust B cell behavior in the prevention, diagnosis, and treatment of autoimmune diseases.
Editor’s Note: The research described in the Nature Immunology paper was funded in part by the National Institute of Allergy and Infectious Disease and the National Institute on Aging. The research described in the PNAS paper was funded in part by a sponsored research agreement with Human Genome Sciences, Inc.
PENN Medicine is a $3.6 billion enterprise dedicated to the related missions of medical education, biomedical research, and excellence in patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System.
Penn's School of Medicine is currently ranked #4 in the nation in U.S.News & World Report's survey of top research-oriented medical schools; and, according to most recent data from the National Institutes of Health, received over $379 million in NIH research funds in the 2006 fiscal year. Supporting 1,700 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.
The University of Pennsylvania Health System (UPHS) includes its flagship hospital, the Hospital of the University of Pennsylvania, rated one of the nation’s top ten “Honor Roll” hospitals by U.S.News & World Report; Pennsylvania Hospital, the nation's first hospital; and Penn Presbyterian Medical Center. In addition UPHS includes a primary-care provider network; a faculty practice plan; home care, hospice, and nursing home; three multispecialty satellite facilities; as well as the Penn Medicine Rittenhouse campus, which offers comprehensive inpatient rehabilitation facilities and outpatient services in multiple specialties.
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $5.3 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 18 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $373 million awarded in the 2015 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2015, Penn Medicine provided $253.3 million to benefit our community.